Mounjaro Dosage Chart & Titration Schedule

Mounjaro starts at 2.5 mg once weekly, but moving through every strength is not automatic. This US guide covers conditional dose increases, adult and pediatric limits, identifying the actual pen or vial, KwikPen use, storage and missed-dose timing. It also separates trial-level side-effect evidence from predictions about how a particular dose will feel.

Mounjaro Dosage Overview

Mounjaro (tirzepatide) has six labeled strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg per weekly injection. The current US indication includes glucose control alongside diet and exercise in adults and children aged 10 years and older with type 2 diabetes, and cardiovascular risk reduction in high-risk adults with type 2 diabetes. This chart describes the US Mounjaro label, not an interchangeable Zepbound weight-management schedule.

The August 2026 prescribing information starts at 2.5 mg once weekly and allows 2.5 mg increases after at least four weeks on the current dose if additional glycemic control is needed. Increases are conditional, not automatic. The maximum is 15 mg for adults and 10 mg for pediatric patients; a higher ceiling does not make it everyone's target.

Complete Mounjaro Dosage Chart

Standard Titration Schedule

This is an illustration of the earliest successive adult increases when each is clinically needed and the prescriber proceeds after the minimum four weeks. Five increases from 2.5 to 15 mg require 20 elapsed weeks, so the first 15 mg dose would be at the start of week 21, not after 16 weeks. Many treatment paths do not use every row. Never accelerate because of the calendar or persist with severe symptoms just to complete an interval.

Pen Color Identification & Storage

Use the printed label rather than a generic color chart to identify a dose. The current US label lists six strengths across single-dose pens and vials, multi-dose vials and four-dose KwikPens. Packaging appearance alone does not establish the prescribed amount or device instructions.

• Medicine and strength: Confirm Mounjaro and the prescribed amount per injection, not just the total medicine in the container.
• Presentation: Determine whether it is a single-dose device, multi-dose vial or KwikPen. A KwikPen contains four doses, not one.
• Prescription match: Check any changed strength or presentation with the pharmacist and obtain the corresponding instructions.
• Condition and date: Check expiration, storage history and appearance. Do not use frozen medicine or a damaged pen.

Storage depends on the presentation. The August 2026 label's section 16.2 distinguishes the following limits. Protect all presentations from heat and light, keep the original carton and do not freeze or use medicine that has frozen. Track room-temperature exposure and first use; returning a product to the refrigerator does not reset its cumulative allowance.

• Single-dose pen or vial: Refrigerate at 2–8°C (36–46°F). If needed, it may be kept at temperatures no higher than 30°C (86°F) for a total of 21 days, after which it must be discarded. A single-dose vial is not a reusable multi-dose supply.
• Unopened multi-dose vial or KwikPen: Refrigerated storage at 2–8°C permits use until the labeled expiration date. If stored at room temperature up to 30°C, discard after 30 days.
• Opened multi-dose vial or KwikPen: Store in the original carton refrigerated at 2–8°C or at room temperature up to 30°C. Discard at the earliest of a total of 30 days at room temperature, 30 days after first use or four weekly doses, even if medicine remains.

How to Use the Mounjaro KwikPen

The US Mounjaro KwikPen is a single-patient pen containing four fixed weekly doses, not a single-dose autoinjector. The following overview follows the US KwikPen Instructions for Use. Get training for the actual presentation and use the illustrated instructions supplied with it; another pen's steps are not interchangeable.

Before Injection

1. Check the prescription and pen: Wash your hands, remove the pen cap and check the medicine name, dose strength, expiration date and condition. Do not use a damaged, expired or previously frozen pen. The solution should be clear and colorless to slightly yellow, without particles or cloudiness.
2. Attach a new needle: Wipe the red inner seal with alcohol. Attach a new KwikPen-compatible needle as illustrated. Remove both needle shields; keep the outer shield for removal after injection and discard the inner shield. Needles are not included with the pen.
3. Prime each time: Follow the IFU's priming steps before every weekly injection. The prime marker is not the weekly dose setting. With the needle pointing up, release the priming amount into the air while holding the knob and slowly counting to five. Confirm a drop appears; if it does not, follow the IFU's limited repeat/needle-change sequence or contact Lilly rather than injecting an unverified dose.
4. Choose the site: Use the abdomen at least two inches from the belly button or the thigh; another person should inject the back of the upper arm. Rotate the exact site each week.

During Injection

1. Select the full dose: Turn the knob all the way until it stops and the 1 indicator appears. Do not select a dose by counting clicks.
2. Inject and hold: Insert the needle as trained, push the knob until it stops and hold it while slowly counting to five. Confirm 0 in the dose window before removing the needle.
3. Check completion: The zero indicator confirms the full dose. If it is absent, follow the IFU's completion instructions without redialing. If you still think the dose was incomplete, do not start over or repeat the entire injection; seek product-specific help.

After Injection

1. Use light pressure if needed: If you see blood, press lightly with gauze or a cotton ball. Do not rub or massage the injection site.
2. Remove the pen needle: Carefully replace its outer shield, unscrew the capped needle and put it in a sharps container. This shield-removal process is specific to the pen needle; it is not a general instruction to recap syringe needles.
3. Store the pen correctly: Replace the pen cap and store it without a needle attached. Follow the presentation-specific discard limits above and in the current labeling. Never share the pen, transfer its contents to a syringe or inject leftover medicine after four doses.
4. Record the dose: Log the injection and first-use date. Follow local disposal rules for the needle-free pen and sharps container; loose needles do not go in household trash.

Side Effects by Dose Level

The prescribing information's adverse-reaction section reports nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain among common effects. Its pooled adult placebo-controlled data compare 5, 10 and 15 mg groups; those group rates do not form a week-by-week symptom forecast for an individual.

2.5 mg (Starting Dose)

This is the labeled starting amount. The pooled common-adverse-reaction table does not supply a standalone 2.5 mg rate that would justify promising minimal nausea or symptoms that pass within a few hours. Record your own response rather than treating an expected appetite change as proof the dose is right.

5 mg

The adult trial data include a 5 mg group, but moving to this amount does not establish that a specific person will develop constipation or that symptoms will resolve within four weeks. The prescriber can assess symptoms alongside glucose control and other medicines.

7.5 mg

The label's pooled common-adverse-reaction table does not identify 7.5 mg as a universal peak-discomfort dose. Reports that a particular step felt harder can be useful personal observations, but they do not establish the frequency, severity or duration everyone should expect.

10 mg & Above

Higher-dose groups still experienced gastrointestinal adverse reactions. The label reports that nausea, vomiting and diarrhea often occurred during escalation and decreased over time, but that is not a guarantee that increasing a dose makes it easier to tolerate. Individual response, time on treatment and dose level are different factors.

Severe or persistent gastrointestinal symptoms warrant contact with the treating team, not waiting until the next escalation date. Persistent or severe abdominal pain, sometimes spreading to the back, can require assessment for pancreatitis; if suspected, stop Mounjaro and seek care. Serious allergic symptoms require urgent attention. The label also flags dehydration-related kidney injury and increased hypoglycemia risk with insulin or sulfonylureas. Mounjaro is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC), MEN 2 or serious hypersensitivity to tirzepatide or its ingredients.

Dose changes can affect other medicines: the label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting Mounjaro and after each dose increase. Review the full medication list with the prescriber.

If more than the prescribed amount was taken, contact the prescriber or US Poison Help, listed in label section 10, at 1-800-222-1222 promptly. The appropriate observation and treatment depend on the situation; do not create your own compensating schedule.

Missed Dose & Dose Adjustment Guidance

What If I Miss an Injection?

The label allows a missed dose within 96 hours of the scheduled time. For example, a dose scheduled Monday at 8 AM can be taken up to Friday at 8 AM. If taken then, the next Monday at 8 AM is 72 hours later. Exact elapsed time matters, not just the names of the days.

If more than 96 hours have passed, skip the missed dose and resume on the regular day. Keep at least 72 hours between injections, including a change of weekly day. Do not double up. A rule against two injections in the same calendar week would misstate the actual spacing requirement.

Can I Stay at a Lower Dose?

The maximum is not a universal target. The current Mounjaro label makes increases conditional on additional glycemic control being needed, and ongoing treatment should reflect the indication, response and tolerability. A weight goal alone does not determine that a dose should be continued indefinitely. Discuss the treatment plan and monitoring with the prescriber.

Skipping or Extending the Gap Between Doses

People may consider longer intervals because of symptoms, cost or access, but that is not the same as following the missed-dose rule. The label does not supply one restart schedule for every interruption or prove that occasional missed doses are consequence-free. After a longer break, discuss the gap, glucose control, prior symptoms and other medicines before resuming. Do not infer a restart amount from a generic chart.

Tips for Successful Dosing

• Mark your calendar: Set a weekly reminder on your phone for the same day and time each week (e.g., every Monday at 8 AM)
• Rotate the exact injection site: Record where the previous dose was given and follow the actual product's site instructions.
• Keep a simple log: Write down each injection date and any side effects you experience to share with your provider
• Review before increasing: Four weeks is the minimum between increases, not an instruction to endure severe or persistent symptoms.
• Watch fluid loss: Vomiting or diarrhea can cause dehydration. Contact the treating team if symptoms persist or fluids cannot be kept down.
• Meals are optional: The label permits use with or without food; an individual meal-timing preference is not a proven nausea-prevention method.
• Verify the product: Keep the carton, prescription details and instructions available so the pharmacist or prescriber can confirm the strength and presentation.

Related Guides & Resources

For more information about Mounjaro and related treatments, explore these guides:

• Tirzepatide: Complete Overview
• Mounjaro Coupon & Savings
• Mounjaro vs. Ozempic Comparison
• Compounded Tirzepatide Guide